The abstract is read at the publisher; the summary is JClub's.
Nicotinamide riboside supplementation markedly attenuates imiquimod-induced psoriasiform skin inflammation in mice, reducing epidermal thickening and splenomegaly while lowering IL-17A–linked T-cell responses.
- Why it matters: Psoriasis involves dysregulated immunity with IL-17–producing T cells as a key driver, but in vivo evidence for nicotinamide riboside’s immunomodulatory effects has been limited.
- What they did: Mice received nicotinamide riboside during imiquimod-induced inflammation; investigators assessed systemic and skin pathology, used flow cytometry to profile infiltrates, and measured IL-17A, IFN-gamma, and IL-4 after ex vivo TCR stimulation and Th polarization.
- The result: NR reduced inflammatory myeloid populations and decreased dermal TCR gamma delta and CD4+ T cells, while IL-17A production by CD4+ T cells fell in a dose-dependent manner; IFN-gamma and IL-4 were largely unchanged.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.